

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2001 (09.08.2001)

PCT

(10) International Publication Number
WO 01/56594 A1

- (51) International Patent Classification⁷: **A61K 38/23**
- (21) International Application Number: PCT/US01/03212
- (22) International Filing Date: 31 January 2001 (31.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/180,241 4 February 2000 (04.02.2000) US
- (71) Applicant: **UNIGENE LABORATORIES, INC.**
[US/US]; 110 Little Falls Road, Fairfield, NJ 07004 (US).
- (72) Inventor: **STERN, William**; 113 Surrey Lane, Tenafly, NJ 07670 (US).
- (74) Agents: **GRAY, William, O., III.** et al.; Ostrolenk, Faber, Gerb & Soffen, LLP, 1180 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/56594 A1

(54) Title: NASAL CALCITONIN FORMULATIONS

(57) Abstract: A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about 10 to about 50 mM, said composition being in a form suitable for nasal administration.

NASAL CALCITONIN FORMULATIONS

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

5 The present invention relates to an intranasal pharmaceutical compositions comprising calcitonin as an active ingredient and specific concentrations of citric acid or a salt thereof as a stabilizer and absorption enhancer.

DESCRIPTION OF THE RELATED ART

10 Calcitonins are a class of polypeptide hormones that are used in the treatment of a variety of conditions including osteoporosis, Paget's disease and malignant hypercalcemia. They are composed of amino acids and have been extracted from a number of sources
15 including salmon, porcine, eel and human. Calcitonins with amino acid sequences identical to the natural forms have been produced by chemical synthesis as well as by recombinant technology.

20 Given their size and chemical composition, calcitonins were originally administered by subcutaneous or intramuscular injection. Other routes of administration were technically difficult because calcitonins were poorly absorbed through tissue and

- 2 -

were readily degraded by bodily fluids. Despite these obstacles, a formulation (U.S. Patent 5,759,565) was developed that could be administered via the nasal route. The nasal formulation was designed to be stored
5 in a multi-dose container that was stable for an extended period of time and resisted bacterial contamination. The preservative in the formulation, benzalkonium chloride, was found to enhance the absorption of salmon calcitonin. However, benzalkonium
10 chloride was reported (P. Graf et al., Clin. Exp. Allergy 25:395-400; 1995) to aggravate rhinitis medicamentosa in healthy volunteers who were given a decongestant nasal spray containing the preservative. It also had an adverse effect on nasal mucosa (H.
15 Hallen et al., Clin. Exp. Allergy 25:401-405; 1995). Berg et al. (Laryngoscope 104:1153-1158; 1994) disclose that respiratory mucosal tissue that was exposed *in vitro* underwent severe morphological alterations. Benzalkonium chloride also caused significant slowing
20 of the mucociliary transport velocity in the *ex vivo* frog palate test (P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992).

SUMMARY OF THE INVENTION

Accordingly, the present invention provides a
25 liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from about 10 to about 50 mM, said composition being in a form suitable for nasal administration.

- 3 -

The present invention also provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% Tween 80.

The present invention further provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% Tween 80.

The present invention also provides a method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering via the nasal route to said subject a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about 10 to about 50 mM.

The present invention further provides a method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition.

The present invention also provides a method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition

- 4 -

of calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition prior to said administration.

5 **DETAILED DESCRIPTION OF THE INVENTION**

In accordance with the present invention it has now been surprisingly found that pharmaceutical compositions can be obtained comprising a calcitonin as active ingredient which meet the high standards of
10 stability and bioavailability required for nasal application and which are, for example, eminently suitable for use in multiple dose nasal spray applicators, i.e., applicators capable of delivering a series of individual dosages over, e.g., period of
15 several days or weeks, by the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM as a buffering agent.

Surprisingly, it has also been found that use of citric acid or a salt thereof at increasing
20 concentrations confers beneficial advantages in relation to the nasal absorption characteristics of calcitonin containing compositions and hence enhance calcitonin bioavailability levels consequential to nasal application. In addition, it has also been found
25 that the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM increase the stability of calcitonin containing compositions while at the same time higher concentrations of citric acid or salt thereof did not

- 5 -

have the same stabilizing effect.

The calcitonins for use in the invention may be in free form or in pharmaceutically acceptable salt or complex form, e.g. in pharmaceutically acceptable acid addition salt form. Such salts and complexes are known and possess an equivalent degree of activity and tolerability to the free forms. Suitable acid addition salt forms for use in accordance with the invention include for example the hydrochlorides and acetates.

The above defined compositions may be applied in accordance with the invention to the nasal mucosa, e.g. either in drop or in spray form. As hereinafter described however, they are most preferably applied in spray form, i.e., in the form of finely divided droplets.

The compositions of the invention may of course also include additional ingredients, in particular components belonging to the class of conventional pharmaceutically applicable surfactants. In this connection it has in accordance with a further aspect of the present invention been found that the use of surface active agents generally in relation to the nasal application of calcitonins, in particular salmon calcitonin, may increase absorption via the nasal mucosa and hence improve obtained bioavailability rates.

Preferably, the liquid pharmaceutical calcitonin

- 6 -

composition of the present invention contains a pharmaceutically acceptable, a liquid diluent or carrier suitable for application to the nasal mucosa, most preferably aqueous saline.

5 The compositions of the invention are formulated so as to permit administration via the nasal route. For this purpose they may also contain, e.g. minimum amounts of any additional ingredients or excipients desired, for example, additional preservatives or, e.g.
10 ciliary stimulants such as caffeine.

 Generally for nasal administration a mildly acid pH will be preferred. Preferably the compositions of the invention have a pH of from about 3 to 5, more preferably from about 3.5 to about 3.9 and most
15 preferably 3.7. Adjustment of the pH is achieved by addition of an appropriate acid, such as hydrochloric acid.

 The compositions of the invention should also possess an appropriate isotonicity and viscosity.
20 Preferably they have an osmotic pressure of from about 260 to about 380 mOsm/liter. Desired viscosity for the nasal spray is preferably less than 0.98 cP.

 Compositions in accordance with the present invention may also comprise a conventional surfactant,
25 preferably a non-ionic surfactant.

 When a surfactant is employed, the amount present

- 7 -

in the compositions of the invention will vary depending on the particular surfactant chosen, the particular mode of administration (e.g. drop or spray) and the effect desired. In general, however, the amount present will be of the order of from about 0.1 mg/ml to about 10 mg/ml, preferably about 0.5 mg/ml to 5 mg/ml and most preferably about 1 mg/ml.

The amount of calcitonin to be administered in accordance with the method of the invention and hence the amount of active ingredient in the composition of the invention will, of course, depend on the particular calcitonin chosen, the condition to be treated, the desired frequency of administration and the effect desired.

As indicated in the following examples, bioavailability for calcitonins, in particular salmon calcitonin, as determined in terms of blood-plasma concentration following nasal administration in accordance with the teachings of the present invention has been found to be surprisingly high.

For nasal administration in accordance with the present invention, treatment will therefore suitably comprise administration of dosages of from about 50 to about 400 MRC units, more preferably from about 100 to about 200 MRC units at a frequency of from about once daily to about three times weekly. Conveniently dosages as aforesaid will be administered in a single application, i.e., treatment will comprise

- 8 -

administration of single nasal dosages comprising about 50 to about 400 MRC units, preferably about 100 to about 200 MRC units, calcitonin. Alternatively such dosages may be split over a series of 2 to 4 applications taken at intervals during the day, the dosage at each application then comprising about 10 to about 200, preferably about 25 to about 100 MRC units.

The total composition quantity administered at each nasal application suitably comprises from about 0.05 to 0.15 ml, typically about 0.1 ml. Compositions for use in accordance with the invention accordingly suitably comprise from about 150 to about 8,000, preferably from about 500 to about 4,000, more preferably from about 500 to about 3,000, yet again more preferably from about 1,000 to about 2,500, and most preferably about 2,200 MRC units of calcitonin per ml.

For the purposes of nasal administration, the compositions of the invention will preferably be put up in a container provided with means enabling application of the contained composition to the nasal mucosa, e.g. put up in a nasal applicator device. Suitable applicators are known in the art and include those adapted for administration of liquid compositions to the nasal mucosa in drop or spray form. Since dosaging with calcitonins should be as accurately controlled as possible use of spray applicators for which the administered quantity is susceptible to precise regulation will generally be preferred. Suitable

- 9 -

administrators include, e.g. atomizing devices, e.g. pump-atomizers and aerosol dispensers. In the latter case, the applicator will contain a composition in accordance with the invention together with a
5 propellant medium suitable for use in a nasal applicator. The atomizing device will be provided with an appropriate spray adaptor allowing delivery of the contained composition to the nasal mucosa. Such devices are well known in the art.

10 The container, e.g. nasal applicator, may contain sufficient composition for a single nasal dosaging or for the supply of several sequential dosages, e.g. over a period of days or weeks. Quantities of individual dosages supplied will preferably be as hereinbefore
15 defined.

The stability of the compositions of the invention may be determined in conventional manner. As indicated hereinbelow, the calcitonin content of the compositions of the invention will degrade less than 50% in 15 days
20 at 50°C as indicated by standard analytical tests.

EXPERIMENTAL DESIGN - METHODS OF ADMINISTERING NASAL
CALCITONIN AND MEASUREMENT OF PLASMA CONCENTRATION

Female Wistar rats, weighing between 225 and 250 g are anesthetized with a combination of ketamine and xylazine, and a cannula is inserted into the carotid
25 artery. The cannula is fitted to a three-way valve through which blood is sampled and replaced with physiological saline containing heparin. Formulated salmon calcitonin (sCT) (5 μ g per 25 μ l) is administered

- 10 -

intranasally through a micropipette tip that was inserted 8 mm into the rat's nostril. For single-dose studies, 5 μ g of sCT was administered. In multiple dose studies, sCT was administered four times in a volume of 25 μ l each at 0, 30, 60 and 90 minutes for a total dose of 20 μ g.

In single-dose studies, blood samples are collected prior to dosing and at 5, 15, 30, 60 and 120 minutes after dosing. In multiple-dose studies, blood samples are collected prior to dosing and at 30, 60, 90, 120 and 150 minutes after the administration of the first dose. Blood samples are always collected immediately before the administration of any additional costs.

Each sample (0.5 ml) of blood is collected into a heparinized 1 ml syringes and then transferred to chilled 1.5 ml polypropylene tubes containing 10 μ l of heparin (500 U per ml). The tubes are centrifuged at approximately 3000 rpm for 20 minutes at 2-8°C and the plasma supernatant is transferred to microcentrifuge tubes that were stored at -20°C. The concentration of sCT in plasma is determined by a competitive radioimmunoassay. Aliquots of the plasma samples and standards are incubated for 4 hours at room temperature with rabbit anti-sCT antibody. Subsequently, ¹²⁵I-sCT is added and incubated overnight at 2-8°C. Antibody-bound ¹²⁵I-sCT is isolated the next day by precipitating it with normal rabbit antiserum and goat anti-rabbit antibody. Radioactivity associated with the resulting

- 11 -

pellets is measured with a gamma counter. The concentration of sCT in plasma is inversely proportional to the amount of radioactivity that was precipitated.

5 The values of Cmax are determined by inspection and the values for bioavailability (relative to an intravenous injection) are calculated from the areas under the curve that were obtained from plots of plasma sCT concentration as a function of time.

10 Example 1

 The following study examines the effect of the concentration of citric acid on the bioavailability and plasma concentration of nasally administered salmon calcitonin. Rats were administered intranasally as
15 described previously 20 μ l of rsCT (200 μ g/ml) in 0.85% sodium chloride, 0.1% Tween 80, 0.2% phenylethyl alcohol, 0.5% benzyl alcohol and varying amounts of citric acid adjusted to pH 3.7 at t=0, 20, 60 and 90 minutes. Samples of blood were taken prior to the
20 administration of rsCT at these time points as well as at t=120 and 150 minutes. The resulting plasma samples were analyzed for rsCT by radioimmunoassay. Maximum rsCT levels were detected at t=120 minutes. The
25 results of this study as shown in Table 1 indicate that the bioavailability and peak concentration of rsCT was a function of the concentration of citric acid in the formulation.

- 12 -

TABLE 1
 EFFECT OF THE CONCENTRATION OF CITRIC ACID ON THE
 BIOAVAILABILITY AND PLASMA CONCENTRATION OF
SALMON CALCITONIN ADMINISTERED INTRANASALLY TO RATS

5	Citric acid (pH 3.7) mM	Bioavailability (percent \pm sdev)	Maximum plasma sCT (ng/ml \pm sdev)
	0	0.89 \pm 0.19	1.10 \pm 0.52
	10	3.14 \pm 1.77	3.66 \pm 1.67
10	25	5.01 \pm 2.34	5.11 \pm 2.09
	50	6.15 \pm 1.31	6.05 \pm 1.30
	100	13.36 \pm 3.38	12.98 \pm 3.96

Example 2

The following study examines the effect of
 15 different preservatives on the plasma concentration of
 nasally administered salmon calcitonin. Rats were
 administered intranasally as described previously 20 μ l
 of sCT (200 μ g/ml) in 0.85% sodium chloride, 0.1% Tween
 80 and a combination preservatives of either 0.2%
 20 phenylethyl alcohol and 0.5% benzyl alcohol or 0.27%
 methyl parabens and 0.04% propyl parabens at t=0, 30,
 60 and 90 minutes. The results of this study as shown
 in Table 2 indicate that the bioavailability and peak
 concentration of rsCT are not significantly affected by
 25 the addition of the different preservatives.

TABLE 2
EFFECT OF PRESERVATIVES ON THE
AVAILABILITY AND PLASMA CONCENTRATION
OF SCT ADMINISTERED INTRANASALLY TO RATS

5	Preservatives	Bioavailabilit y (percent ± sdev)	Maximum plasma sCT (ng/ml ± sdev)
	None	1.14 ± 0.87	1.24 ± 0.79
	0.2% phenylethyl alcohol - 0.5% benzyl alcohol	0.89 ± 0.19	1.10 ± 0.52
10	0.27 methyl parabens - 0.04% propyl parabens	1.08 ± 0.86	1.47 ± 1.46

Example 3

The following study examines the effect of the concentration of citric acid on the stability of salmon calcitonin stored for varying periods at a temperature of 50°C. Nasal formulations containing sCT (200µg/ml), 0.25% phenylethyl alcohol, 0.5% benzyl alcohol and 0.1% Tween 80 were adjusted to pH 3.7 with either HCl or the indicated amount of buffered citric acid. The formulations were stored at 50°C in sealed glass containers for the indicated amount of time and analyzed for sCT by high performance liquid chromatography. The results as shown in Table 3 indicate that in the absence of citric acid, the amount sCT in the formulation decreased steadily between 0 and 9 days after the study was begun. In the presence of citric acid (10-50 mM) the rate of disappearance of sCT decreased significantly.

However, as the concentration of citric acid was further increased, the rate of sCT disappearance from vials stored at 50°C increased in proportion to the amount of buffered citric acid in the formulation.

5

TABLE 3

EFFECT OF THE CONCENTRATION OF
CITRIC ACID ON THE STABILITY OF
sCT STORED FOR VARYING PERIODS AT 50°C

Percent sCT Recovered					
Citric Acid (pH 3.7)	0 mM	10 mM	20 mM	50 mM	100 mM
Days at 50°C					
0	100	100	100	100	100
3	83	94	91	90	87
6	53	90	87	83	77
9	24	82	78	73	66
15	22	74	68	61	20

10

15

WHAT IS CLAIMED IS:

1. A liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from about 10 to about 50 mM, said composition being in a form suitable for nasal administration.

5

2. The liquid pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable, aqueous liquid nasal carrier.

3. The liquid pharmaceutical composition of claim 2, wherein said carrier comprises aqueous saline.

4. The liquid pharmaceutical composition of claim 1, wherein said composition is in the form of a nasal spray.

5. The liquid pharmaceutical composition of claim 4 having a viscosity of less than 0.98 cP.

6. The liquid pharmaceutical composition of claim 1, wherein the calcitonin is selected from the group consisting of salmon calcitonin, human calcitonin, porcine calcitonin and 1,7-Asu-eel calcitonin.

7. The liquid pharmaceutical composition of claim 1, wherein the calcitonin is salmon calcitonin.

8. The liquid pharmaceutical composition of claim

- 16 -

1, wherein said calcitonin, or salt is present in an amount of from about 100 to about 8,000 MRC units/ml.

9. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 500 to about 4,000 MRC units/ml.

10. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 500 to about 3,000 MRC units/ml.

11. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 1,000 to about 2,500 MRC units/ml.

12. The liquid pharmaceutical composition of claim 1 having a pH of from about 3 to about 5.

13. The liquid pharmaceutical composition of claim 1 having a pH of from about 3.5 to about 3.9.

14. The liquid pharmaceutical composition of claim 1 having a pH of about 3.7.

15. The liquid pharmaceutical composition of claim 1 having an osmotic pressure of from about 250 to about 350 mOsm/liter.

16. The liquid pharmaceutical composition of claim 1 further containing at least 0.1% by weight of Tween 80.

- 17 -

17. The liquid pharmaceutical composition of claim 1 further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.

18. A liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% Tween 80.

19. A liquid pharmaceutical composition comprising about 2,200 MIC units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% Tween 80.

20. A method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering to said subject a composition as defined in claim 1 via the nasal route.

21. The method of claim 20, wherein the amount of calcitonin administered is from about 200 to about 600 MRC units.

22. A method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition.

23. A method of improving the bioavailability or

- 18 -

the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of calcitonin, which method comprises adding
5 citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition prior to said administration.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/03212

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 38/23
US CL :514/12, 21; 530/307

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12, 21; 530/307

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	US 6,087,338 A (VERONESI ET AL) 11 July 2000 (11/7/00), see entire document.	1-23 -
X	US 5,059,587 A (YAMAMOTO ET AL) 22 October 1991 (22/10/91), see entire document.	1-23

Further documents are listed in the continuation of Box C. See patent family annex.

<p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p>	<p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>* & * document member of the same patent family</p>
--	---

Date of the actual completion of the international search

08 APRIL 2001

Date of mailing of the international search report

27 APR 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FREDERICK KRASS 

Telephone No. (703) 308-1235